

October 24, 2019

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (1<sup>st</sup> Section of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
President & CEO: Tatsuro Kosaka  
Inquiries to: Masahiko Uchida, General Manager,  
Corporate Communications Dept.  
Tel: +81-(0)3-3273-0881

## Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year

Chugai Pharmaceutical Co., Ltd. hereby announces that there is a difference regarding the individual financial results (Japanese standard) for the nine months ended September 30, 2019 (Jan. 1, 2019 – Sep. 30, 2019) as compared to the actual results for the previous year (Jan. 1, 2018 – Dec. 31, 2018).

### 1. Difference between the actual results for the nine months ended September 30, 2019 and the actual results for the previous year

	Revenues	Operating Income	Ordinary Income	Net Income	Earnings per Share
Actual results for the previous year (A) (Jan. 1, 2018 – Dec. 31, 2018)	(millions of yen) 571,740	(millions of yen) 109,566	(millions of yen) 113,794	(millions of yen) 86,529	(Yen Sen) 158.18
Actual results for this year (B) (Jan. 1, 2019 – Sep. 30, 2019)	(millions of yen) 502,539	(millions of yen) 155,694	(millions of yen) 158,791	(millions of yen) 114,736	(Yen Sen) 209.62
Change (B-A)	(millions of yen) △69,201	(millions of yen) 46,128	(millions of yen) 44,997	(millions of yen) 28,207	-
Change (%)	△12.1	42.1	39.5	32.6	-

### 2. Reasons for the difference occurring

The difference occurred mainly due to the strong performance of new products and mainstay products in the domestic market, increase in exports to Roche, increase in royalties and other operating income, and improvement in cost of sales due to changes in product mix, etc.

###